Log In
Print this Print this

Anti-vWF Nanobody, caplacizumab (ALX-0081/ALX-0681)

  Manage Alerts
Collapse Summary General Information
Company Ablynx N.V.
DescriptionNanobodies targeting von Willebrand factor (vWF)
Molecular Target von Willebrand factor (vWF)
Mechanism of Actionvon Willebrand factor (vWF) inhibitor; Antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationThrombocytopenia
Indication DetailsTreat thrombotic thrombocytopenic purpura (TTP)
Regulatory Designation U.S. - Orphan Drug (Treat thrombotic thrombocytopenic purpura (TTP));
EU - Orphan Drug (Treat thrombotic thrombocytopenic purpura (TTP))

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today